Skip to content
10-Q

Quarterly Report

CYTOKINETICS INC CYTK

0001193125-26-206364

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 4, 2026 124.43M sh
Shares Diluted Q1 2026 · Mar 31, 2026 123.27K sh
Shares Diluted Q1 2026 · Mar 31, 2025 118.5K sh
Capex Q1 2026 · Mar 31, 2026 $5.93M
Capex Q1 2026 · Mar 31, 2025 $5.66M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$145.46M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$131.62M
Long Term Debt Q1 2026 · Mar 31, 2026 $247.21M
Long Term Debt Q1 2026 · Dec 31, 2025 $246.38M
Short Term Debt Q1 2026 · Mar 31, 2026 $44.81M
Short Term Debt Q1 2026 · Dec 31, 2025 $41.18M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $129.84M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $122.52M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$826.57M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$659.63M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$266.41M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$135.37M
Current Liabilities Q1 2026 · Mar 31, 2026 $199.19M
Current Liabilities Q1 2026 · Dec 31, 2025 $202.45M
Total Liabilities Q1 2026 · Mar 31, 2026 $2.1B
Total Liabilities Q1 2026 · Dec 31, 2025 $2.08B
Current Assets Q1 2026 · Mar 31, 2026 $839.47M
Current Assets Q1 2026 · Dec 31, 2025 $916.98M
Total Assets Q1 2026 · Mar 31, 2026 $1.27B
Total Assets Q1 2026 · Dec 31, 2025 $1.42B
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.67
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.36
Eps Basic Q1 2026 · Mar 31, 2026 −$1.67
Eps Basic Q1 2026 · Mar 31, 2025 −$1.36
Sga Expense Q1 2026 · Mar 31, 2026 $104.9M
Sga Expense Q1 2026 · Mar 31, 2025 $57.37M
Rd Expense Q1 2026 · Mar 31, 2026 $95.53M
Rd Expense restated Q1 2026 · Mar 31, 2025 $98.26M
Net Income Q1 2026 · Mar 31, 2026 −$206.03M
Net Income Q1 2026 · Mar 31, 2025 −$161.38M
Operating Income Q1 2026 · Mar 31, 2026 −$183.62M
Operating Income Q1 2026 · Mar 31, 2025 −$155.63M
Revenue Q1 2026 · Mar 31, 2026 $19.36M
Revenue Q1 2026 · Mar 31, 2025 $1.58M